March 11, 2026, marked a significant milestone for Yatsen Holding Limited, the Chinese beauty group listed on the New York Stock Exchange. On this day, the company announced its intention to issue $120 million in convertible preferred notes through a private placement. The subscribers are a special purpose vehicle formed by the company's founder, chairman, and CEO, Mr. Huang Jinfeng, in conjunction with CITIC Capital.

The announcement was met with a positive reaction in the capital markets. Following the pre-market release, Yatsen's stock price opened significantly higher, closing at $4.22, a gain of 10.47%. Against a backdrop of fragile market sentiment and overall volatility for U.S.-listed Chinese stocks, this surge appeared to be more than just a reaction to short-term liquidity; it resembled a market vote of confidence in Yatsen's intensive, four-year-long transformation.

For Yatsen, which reported cash and short-term investments of approximately 1.05 billion yuan (as of the end of 2025), this $120 million is not a "lifeline" but a crucial "stimulant" and "accelerator." This analysis delves into the deeper rationale behind this fundraising: How has Yatsen evolved from the traffic-driven "Perfect Diary" to a new beauty giant where skincare now constitutes over half its business, driven by R&D, and boldly leveraging capital for global expansion? And what challenges lie ahead for this high-stakes leap?

**Capital Endorsement and Strategic Leap: The "Top-Level Design" Behind $120 Million**

The details of this financing reveal several significant signals.

First is the model of joint leadership by the "founder + top-tier PE firm." Mr. Huang Jinfeng's increased investment signals management's firm belief in the company's long-term value—a reassuring move when the stock price is near historical lows (52-week low: $3.30). The involvement of CITIC Capital indicates ambitions beyond mere financial support.

CITIC Capital is not just a capital provider but a resource integrator. The announcement explicitly notes CITIC Capital's deep presence in the beauty supply chain: its controlled entity, Axilone, is one of the world's largest cosmetic packaging suppliers, serving numerous international premium brands. Furthermore, CITIC Capital's extensive portfolio in pharmaceuticals and biotech can provide critical support for Yatsen's cutting-edge product development.

A statement from CITIC Capital's chairman, Mr. Zhang Yichen, was particularly telling: "We look forward to starting with this cooperation to deeply empower Yatsen, integrating global premium resources through cross-border M&A to help Yatsen achieve the leap from a 'Chinese disruptor' to a 'global beauty group.'" This suggests the financing is not merely a financial investment but a strategic alignment aimed at global supply chain integration and cross-border mergers and acquisitions.

Second is the choice of financing instrument—convertible preferred notes. According to the announcement, the notes carry a low annual coupon of just 1.5%, with an initial conversion price set at $4.63 per ADS, representing a 20% premium over the weighted average price of the preceding five trading days. This hybrid "debt + equity" instrument reflects investor optimism about Yatsen's future share price (accepting low interest for conversion rights) while providing the company with low financing costs and avoiding immediate dilution of existing equity. It represents a savvy financial maneuver at a potential inflection point for the stock.

Finally, the intended use of proceeds is clearly directed. Funds will be allocated to four key areas: product research and development, global supply chain integration, overseas market expansion, and strategic acquisitions. This stands in stark contrast to the early funding rounds, which were primarily used for marketing expenditures. If past fundraising was for "land grabs," this round is for "building moats."

**Early Signs of Transformation: Skincare Carries the Load, But Is the Profit Foundation Solid?**

Any capital move must be supported by fundamentals. CITIC Capital's willingness to invest at this juncture is fundamentally rooted in Yatsen's four-year "second startup" transformation, which finally yielded convincing results in the 2025 financial report.

According to the full-year 2025 results, Yatsen reached several milestone turning points:

First, revenue returned to growth. Total annual revenue for 2025 reached 4.3 billion yuan, a year-on-year increase of 26.7%, surpassing the 4 billion yuan mark for the first time in four years.

Second, the company achieved its first annual Non-GAAP net profit since listing, recording a profit of 8.4 million yuan. Although it reported a slight GAAP net loss of 92.4 million yuan, this loss narrowed significantly from 710 million yuan the previous year, indicating a qualitative improvement in operational quality.

Finally, the skincare business emerged as the true "second growth curve," the core highlight of the transformation. In 2025, net revenue from skincare surged 63.5% year-on-year to 2.28 billion yuan, accounting for 53% of total revenue and surpassing color cosmetics for the first time. This proportion rose further to 61.1% in the fourth quarter. The premium skincare portfolio, centered around brands like Galénic, EVE LOM, and DR.WU, has fundamentally reshaped the company's revenue structure.

This structural shift is critical. If color cosmetics are akin to "fashion derivatives"—characterized by high frequency, low average order value, fast trend cycles, and low loyalty—then premium skincare is a "functional consumable," defined by high technological barriers, stable repurchase rates, and strong brand loyalty.

Yatsen's overall gross margin improved to 78.2% in 2025, precisely due to the increased contribution of high-margin skincare products. The business model is becoming more resilient, shifting from traffic-driven color cosmetics to R&D and brand-driven skincare.

However, a sober assessment of this report card reveals underlying concerns:

First, the stagnation of the core color cosmetics business. Yatsen's color cosmetics revenue grew by a mere 1.9% for the full year 2025, remaining around 2 billion yuan. As traffic costs cease to be an advantage, the moat for "affordable color cosmetics" is extremely fragile. While Perfect Diary is pursuing a "cosmetics-skincare integration" strategy, it still faces intense competition from international giants and emerging brands in the mid-market segment.

Second, the fragility of profitability. In Q4 2025, Non-GAAP net income attributable to shareholders fell 54.6% year-on-year to 46 million yuan, well below market expectations. This was directly attributed to higher customer acquisition costs and increased marketing spending during the "Double 11" shopping festival. This indicates that, even during its transformation, Yatsen has not fully shed its reliance on traffic; volatility in the marketing expense ratio remains a primary risk eroding profits.

Third, cash flow pressure. Despite an improved income statement, net cash flow from operating activities for the full year 2025 remained negative (-94.7 million yuan), and cash and short-term investments decreased by over 300 million yuan compared to the start of the year. This explains the need for the $120 million cash infusion—sustained R&D investment, brand building, and potential acquisitions during the transformation phase require continuous capital investment.

**The Globalization Conundrum: Does Capital in Hand Guarantee a Welcome Overseas?**

Yatsen has identified "global expansion" and "strategic acquisitions" as core objectives of this fundraising. This is undoubtedly the right direction but also the riskiest endeavor.

Historically, international giants like L'Oréal and Estée Lauder built their brand empires through aggressive acquisition strategies. Yatsen's previous acquisitions (such as EVE LOM) have indeed infused it with premium brand DNA. With the backing of CITIC Capital and its industrial resources like Axilone, Yatsen's global ambitions have greater potential.

CITIC Capital's empowerment operates on two main levels:

On one hand, it enables a top-tier upgrade of the supply chain. As a premium packaging supplier, Axilone can help Yatsen's brands match the product quality and aesthetics of international luxury brands, addressing shortcomings in craftsmanship behind "visual appeal."

On the other hand, it aids in the identification and integration of acquisition targets. Leveraging CITIC Capital's global network, Yatsen can more precisely scout overseas niche brands with technological advantages or unique brand identities that have low penetration in China, replicating the success of Galénic through an "introduce and empower" model.

However, having capital and resources does not guarantee success. Yatsen's path to globalization faces at least three major challenges:

First, the potential "lack of fit" for brands going overseas. If acquisitions are about "bringing in," this fundraising also explicitly aims for "going out." While a本土 brand like Perfect Diary might gain traction in Southeast Asia through superior social media marketing, penetrating mature markets like Europe, the US, Japan, and South Korea involves entirely different cultural aesthetics, channel structures (predominantly offline), and consumer perception barriers. Transforming "China's Perfect Diary" into "the world's Perfect Diary" requires more than influencer marketing; it demands localized products and teams. While CITIC Capital's global experience can assist, the actual execution falls on Yatsen itself.

Second, the risk of "big company disease" in multi-brand management. Yatsen's portfolio now spans mass-market color cosmetics (Perfect Diary, Little Ondine) and premium skincare (EVE LOM, Galénic). Brands at different price points, in different segments, and with different origins require distinct organizational structures, channel management, and talent pipelines. As the pace of acquisitions accelerates, preventing internal brand competition, maintaining the independence and creativity of acquired brands, while leveraging group synergies in back-end functions (R&D, supply chain, digitalization) presents a major test for management.

Third, the "long war" of building R&D barriers. The ultimate competition in the cosmetics industry is technological. While Yatsen increased its R&D expenditure to 137 million yuan in 2025, with the R&D expense ratio rising to about 3.2%—leading among domestic peers—it pales in comparison to L'Oréal's annual R&D investment exceeding 1 billion euros. Although this fundraising is earmarked for R&D, establishing a genuine technological moat in core areas like anti-aging, bio-fermentation, and skin science requires the $120 million to be just a starting point, not the finish line.

**The Institutional Viewpoint: Consensus and Risk Amid Divergence**

Wall Street and Chinese brokerages exhibit a stance of "cautious optimism" towards Yatsen's recent moves, reflecting a divergence of views.

Optimists, led by China International Capital Corporation (CICC), maintain an "Outperform" rating. While they lowered near-term profit forecasts due to higher marketing expenses, they raised the target price to $5.80, implying a 53% upside from the current price. Their core logic rests on the positive impact of high skincare growth on revenue structure optimization.

On the cautious side, CITIC Securities maintains a "Neutral" rating. While acknowledging the transformation's success and raising profit forecasts, they refrain from an aggressive recommendation, citing market competition and macroeconomic uncertainties.

This divergence precisely mirrors Yatsen's current situation: the direction is correct, but the path is challenging.

For investors, monitoring several key metrics in the coming periods will be more meaningful than focusing on short-term stock price fluctuations:

First, whether the company can achieve GAAP profitability in the first quarter of 2026: This is a target set by management and a key test of the transformation's substance.

Second, whether the marketing expense ratio can be effectively controlled: In an environment of increasingly expensive traffic, the ability to reduce customer acquisition costs through brand strength is crucial for validating the skincare-driven business logic.

Third, the progress of new acquisitions or existing overseas operations: The timing of when CITIC Capital's resources translate into tangible growth will likely become the next focal point for market speculation or validation.

Yatsen's $120 million fundraising is a microcosm of the Chinese beauty industry's transition from "marketing-driven" to "technology and capital-driven." Mr. Huang Jinfeng and his team are guiding the company through a long tunnel. On one end lies its origin as the "first disruptive beauty stock," renowned for Perfect Diary and riding the wave of traffic红利. On the other end is the vision of a "world-class beauty group" built on a multi-brand portfolio, a global supply chain, and R&D barriers.

This $120 million is a beacon of capital illuminating the path forward, but it may also magnify the shadows ahead. For Yatsen, the real test has just begun. The company must not only tell a compelling story to the capital markets but also secure a genuine place on the vanities of global consumers.